Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition

3 Aug 2022

Abstract excerpt

High Resolution Image Download MS PowerPoint Slide Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are used in ovarian cancer treatment and have greatly improved the survival rates for homologous recombination repair (HRR)-deficient patients. However, their therapeutic efficacy is limited in HRR-proficient ovarian cancer. Thus, sensitizing HRR-proficient ovarian cancer cells to PARP inhibitors is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35920396
DOI: 10.1021/acsnano.2c04956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP InhibitionPMID 35920396Read ↗

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanismsSemantic proximity Read ↗

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Semantic proximity Read ↗

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancerSemantic proximity Read ↗

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer TherapySemantic proximity Read ↗

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian CancersSemantic proximity Read ↗

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitorsSemantic proximity Read ↗

Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compoundsSemantic proximity Read ↗

Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivitySemantic proximity Read ↗

Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells.Semantic proximity Read ↗

Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistanceSemantic proximity Read ↗

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerSemantic proximity Read ↗

Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.